Podcast appearances

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

May 29 · 1h 5m

Amy E. ArmstrongGUEST

1:36

helping pediatric patients transition to adult care.

Angela HirbeGUEST

1:39

So I think pretty good spread.

Angela HirbeGUEST

1:40

I think all of these are challenges that various providers face and all things that, you know, we plan to touch on today.

Angela HirbeGUEST

1:54

So neurofibromatosis type 1 affects about 120,000 Americans and 2 million people worldwide.

Angela HirbeGUEST

2:01

It's a genetic neurocutaneous disorder that predisposes individuals to develop both benign and malignant tumors.

Angela HirbeGUEST

2:08

And it's caused by a mutation in the NF1 gene, which codes for neurofibromin.

Angela HirbeGUEST

2:14

And neurofibromin functions as a tumor suppressor.

28 MINS LATER

Amy E. ArmstrongGUEST

30:20

I

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

May 29 · 1h 5m

Amy E. ArmstrongGUEST

1:37

patients transition to adult care.

Angela HirbeGUEST

1:39

So I think pretty good spread.

Angela HirbeGUEST

1:40

I think all of these are challenges that various providers face and all things that we plan to touch on today.

Angela HirbeGUEST

1:54

So neurofibromatosis type 1 affects about 120,000 Americans and 2 million people worldwide.

Angela HirbeGUEST

2:01

It's a genetic neurocutaneous disorder that predisposes individuals to develop both benign and malignant tumors.

Angela HirbeGUEST

2:08

And it's caused by a mutation in the NF1 gene, which codes for neurofibromin.

Angela HirbeGUEST

2:14

And neurofibromin functions as a tumor suppressor, so losing this results in overactivation of various growth signaling pathways.

28 MINS LATER

Amy E. ArmstrongGUEST

30:19

That's all I know.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

May 29 · 1h 5m

Amy E. ArmstrongGUEST

1:37

patients transition to adult care.

Angela HirbeGUEST

1:39

So I think pretty good spread.

Angela HirbeGUEST

1:40

I think all of these are challenges that various providers face and all things that we plan to touch on today.

Angela HirbeGUEST

1:54

So neurofibromatosis type 1 affects about 120,000 Americans and 2 million people worldwide.

Angela HirbeGUEST

2:01

It's a genetic neurocutaneous disorder that predisposes individuals to develop both benign and malignant tumors.

Angela HirbeGUEST

2:08

And it's caused by a mutation in the NF1 gene, which codes for neurofibromin.

Angela HirbeGUEST

2:14

And neurofibromin functions as a tumor suppressor, so losing this results in overactivation of various growth signaling pathways.

28 MINS LATER

Amy E. ArmstrongGUEST

30:19

That's all I know.

PeerView Clinical Pharmacology CME/CNE/CPE Video

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

May 29 · 1h 5m

Amy E. ArmstrongGUEST

1:37

patients transition to adult care.

Angela HirbeGUEST

1:39

So I think pretty good spread.

Angela HirbeGUEST

1:40

I think all of these are challenges that various providers face and all things that we plan to touch on today.

Angela HirbeGUEST

1:54

So neurofibromatosis type 1 affects about 120,000 Americans and 2 million people worldwide.

Angela HirbeGUEST

2:01

It's a genetic neurocutaneous disorder that predisposes individuals to develop both benign and malignant tumors.

Angela HirbeGUEST

2:08

And it's caused by a mutation in the NF1 gene, which codes for neurofibromin.

Angela HirbeGUEST

2:14

And neurofibromin functions as a tumor suppressor, so losing this results in overactivation of various growth signaling pathways.

28 MINS LATER

Amy E. ArmstrongGUEST

30:19

That's all I know.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

May 29 · 1h 5m

Amy E. ArmstrongGUEST

1:36

helping pediatric patients transition to adult care.

Angela HirbeGUEST

1:39

So I think pretty good spread.

Angela HirbeGUEST

1:40

I think all of these are challenges that various providers face and all things that, you know, we plan to touch on today.

Angela HirbeGUEST

1:54

So neurofibromatosis type 1 affects about 120,000 Americans and 2 million people worldwide.

Angela HirbeGUEST

2:01

It's a genetic neurocutaneous disorder that predisposes individuals to develop both benign and malignant tumors.

Angela HirbeGUEST

2:08

And it's caused by a mutation in the NF1 gene, which codes for neurofibromin.

Angela HirbeGUEST

2:14

And neurofibromin functions as a tumor suppressor.

28 MINS LATER

Amy E. ArmstrongGUEST

30:20

I

Angela Hirbe

May 29, 2026

We value your privacy